The model used to summarize this release may make ... and 62 decrease their positions in their most recent quarter. Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback